Marksans Pharma balance sheet

As of Mar 2026

Total assets: ₹3,861cr+1,091.8% on Mar 2025
Shareholders' equity: ₹3,053cr+1,126.3% on Mar 2025
Total debt: ₹29.6cr+1,181.8% on Mar 2025
Cash and investments: ₹634cr+1,177.1% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	625	57.9	676	380
	14.8	0.9	5.4	7.2
	45.3	4.1	39.5	38.5
	73.0	36.2	60.7	68.2
	43.8	1.8	4.0	2.6
	3.9	0.4	2.6	3.5
	3.9	0.4	2.6	3.5
	13.0	0.1	1.1	0.0
	320	2.2	29.4	15.4
	1,138	104	818	515
	972	84.6	618	485
	0.0	0.1	27.0	0.5
	645	54.0	453	417
	634	49.6	403	382
	356	20.8	270	333
	116	0.4	6.9	3.7
	1,750	125	1,161	1,136
	100	9.8	79.0	52.6
	2,723	220	1,862	1,675
	3,861	324	2,681	2,190
Equity
	45.3	4.5	45.3	45.3
	2,978	242	2,020	1,700
	3,023	247	2,065	1,745
	29.5	2.2	20.9	19.9
	3,053	249	2,086	1,765
Liabilities
	270	26.3	190	65.7
	270	26.3	190	65.7
	5.9	0.6	4.6	3.3
	5.1	0.4	10.6	15.4
	281	27.3	205	84.3
	29.6	2.3	29.1	41.6
	337	30.6	268	231
	73.8	5.9	40.4	31.0
	440	38.8	338	303
	0.3	0.1	2.0	1.3
	41.6	3.0	19.9	25.3
	44.9	5.8	30.2	11.2
	527	47.7	390	341
	808	75.0	595	425
	3,861	324	2,681	2,190
Assets — additional as-filed lines
	1.1	1.2	4.9	1.9
Trade payables — MSME split
	2.0	0.4	—	—
	335	30.2	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	379.6	675.7	57.9	625.0	625.0
+ Capital Work-in-Progress	7.2	5.4	0.9	14.8	14.8
+ Goodwill	38.5	39.5	4.1	45.3	45.3
+ Other Intangibles	68.2	60.7	36.2	73.0	73.0
+ Intangibles under Development	2.6	4.0	1.8	43.8	43.8
+ Other Non-current Financial Assets	3.5	2.6	0.4	3.9	3.9
Non-current Financial Assets	3.5	2.6	0.4	3.9	3.9
+ Deferred Tax Assets	0.0	1.1	0.1	13.0	13.0
+ Other Non-current Assets	15.4	29.4	2.2	319.5	319.5
Total Non-current Assets	515.1	818.5	103.6	1,138.2	1,138.2
Current Assets
+ Inventories	484.7	617.9	84.6	972.3	972.3
+ Current Investments	0.5	27.0	0.1	0.0	0.0
+ Trade Receivables	416.8	453.2	54.0	644.6	644.6
+ Cash & Cash Equivalents	382.4	403.3	49.6	634.1	634.1
+ Other Bank Balances	332.5	270.3	20.8	355.5	355.5
+ Other Current Financial Assets	3.7	6.9	0.4	116.2	116.2
Current Financial Assets	1,136.0	1,160.6	124.9	1,750.5	1,750.5
+ Other Current Assets	52.6	79.0	9.8	100.5	100.5
Total Current Assets	1,675.3	1,862.5	220.4	2,722.7	2,722.7
Total Assets	2,190.4	2,681.0	324.0	3,860.9	3,860.9
Equity
+ Equity Share Capital	45.3	45.3	4.5	45.3	45.3
+ Other Equity / Reserves	1,699.8	2,019.7	242.2	2,977.8	2,977.8
Equity — Owners of Parent	1,745.2	2,065.1	246.7	3,023.2	3,023.2
+ Minority Interest	19.9	20.9	2.2	29.5	29.5
Total Equity	1,765.1	2,085.9	248.9	3,052.7	3,052.7
Liabilities
+ Other Non-current Financial Liab	65.7	190.0	26.3	270.1	270.1
Non-current Financial Liabilities	65.7	190.0	26.3	270.1	270.1
+ Provisions — Non-current	3.3	4.6	0.6	5.9	5.9
+ Deferred Tax Liabilities	15.4	10.6	0.4	5.1	5.1
Non-current Liabilities	84.3	205.2	27.3	281.1	281.1
+ Borrowings — Current	41.6	29.1	2.3	29.6	29.6
+ Trade Payables	230.6	268.3	30.6	336.9	336.9
+ Other Current Financial Liab	31.0	40.4	5.9	73.8	73.8
Current Financial Liabilities	303.1	337.7	38.8	440.3	440.3
+ Provisions — Current	1.3	2.0	0.1	0.3	0.3
+ Current Tax Liabilities	25.3	19.9	3.0	41.6	41.6
+ Other Current Liabilities	11.2	30.2	5.8	44.9	44.9
Current Liabilities	341.0	389.8	47.7	527.1	527.1
Total Liabilities	425.3	595.0	75.0	808.2	808.2
Total Equity & Liabilities	2,190.4	2,681.0	324.0	3,860.9	3,860.9
Assets — additional as-filed lines
+ Current Tax Assets	1.9	4.9	1.2	1.1	1.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	0.4	2.0	2.0
+ Dues to Other Creditors — Current	—	—	30.2	334.9	334.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.